



Patrys Limited
(ACN 123 055 363)

**NOTICE OF ANNUAL GENERAL MEETING AND
EXPLANATORY MEMORANDUM**

Monday, 30 November 2026

1:00pm AWST

To be held in person at

Level 2, 7 Havelock Street, West Perth, Western Australia 6005

The Annual Report is available online at <https://www.patrys.com>

This Notice of Annual General Meeting and Explanatory Memorandum should be read in its entirety. If Shareholders are in doubt as to how to vote, they should seek advice from their accountant, solicitor or other professional adviser without delay.

Should you wish to discuss any matter, please do not hesitate to contact the Company by telephone on +61 8 6165 8858.

NOTICE OF MEETING

Notice is given that the Annual General Meeting of Shareholders of Patrys Limited (ACN 123 055 363) (**Company**) will be held in person at Level 2, 7 Havelock Street, West Perth, Western Australia 6005 on Monday, 30 November 2026 commencing at 1:00pm AWST (**Meeting**).

The Explanatory Memorandum to this Notice provides additional information on matters to be considered at the Meeting. The Explanatory Memorandum and the Proxy Form form part of this Notice.

The Directors have determined pursuant to regulation 7.11.37 of the *Corporations Regulations 2001* (Cth) that the persons eligible to vote at the Meeting are those who are registered as Shareholders at 5:00pm AWST on Saturday, 28 November 2026.

The terms and abbreviations used in this Notice and Explanatory Memorandum are defined in Schedule 1.

AGENDA

Annual Report

To table and consider the Annual Report of the Company and its controlled entities for the financial year ended 30 June 2026, which includes the Financial Report, the Directors' Report and the Auditor's Report.

1. Resolution 1 – Adoption of Remuneration Report

To consider, and, if thought fit, to pass as a **non-binding resolution**, the following:

“That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report that forms part of the Directors' Report for the financial year ended 30 June 2026 be adopted by the Shareholders on the terms and conditions set out in the Explanatory Memorandum.”

Please note that a vote on this Resolution 1 is advisory only and does not bind the Directors or the Company.

Voting Prohibition Statement

In accordance with section 250R of the Corporations Act, a vote on this Resolution 1 must not be cast (in any capacity) by, or on behalf of, a member of the Key Management Personnel whose remuneration details are included in the Remuneration Report, or a Closely Related Party of such a member. However, a vote may be cast by such a person if:

- (a) the person is acting as a proxy and the Proxy Form specifies how the proxy is to vote, and the vote is not cast on behalf of a person who is otherwise excluded from voting on this Resolution 1 as described above; or
- (b) the person is the Chair voting an undirected proxy which expressly authorises the Chair to exercise the proxy even though this Resolution 1 is connected directly or indirectly with the remuneration of a member of the Key Management Personnel.

2. Resolution 2 – Election of Director – Mr Dino Cercarelli

To consider, and, if thought fit, to pass with or without amendment, as an **ordinary resolution**, the following:

“That, for the purposes of clause 15.1(c) of the Constitution, ASX Listing Rule 14.4 and for all other purposes, Mr Dino Cercarelli, a Director who was appointed to fill a casual vacancy on 28 January 2026, retires and, being eligible, is elected as a Director with immediate effect.”

3. Resolution 3 – Election of Director – Ms Leanne Kite

To consider, and, if thought fit, to pass with or without amendment, as an **ordinary resolution**, the following:

“That, for the purposes of clause 15.1(c) of the Constitution, ASX Listing Rule 14.4 and for all other purposes, Ms Leanne Kite, a Director who was appointed to fill a casual vacancy on 28 January 2026, retires and, being eligible, is elected as a Director with immediate effect.”

4. Resolution 4 – Election of Director – Mr Brian Leedman

To consider, and, if thought fit, to pass with or without amendment, as an **ordinary resolution**, the following:

“That, for the purposes of clause 15.1(c) of the Constitution, ASX Listing Rule 14.4 and for all other purposes, Mr Brian Leedman, a Director who was appointed to fill a casual vacancy on 10 November 2025, retires and, being eligible, is elected as a Director with immediate effect.”

5. Resolutions 5(a) and 5(b) – Approval to issue Director Placement Securities (Mr Brian Leedman)

To consider, and, if thought fit, to pass with or without amendment, each of the following as **ordinary resolutions**:

“That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to:

- (a) 2,083,333 Director Placement Shares; and
- (b) 520,833 Director Placement Options,

to Mr Brian Leedman (and/or his nominee(s)), on the terms and conditions set out in the Explanatory Memorandum.”

Voting Exclusion Statement

The Company will disregard any votes cast in favour of the Resolutions by or on behalf of:

- (a) Mr Brian Leedman (and/or his nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company); or
- (b) an Associate of that person or those persons.

However, this does not apply to a vote cast in favour of the Resolutions by:

- (a) a person as proxy or attorney for a person who is entitled to vote on the Resolutions, in accordance with directions given to the proxy or attorney to vote on the Resolutions in that way; or

- (b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolutions, in accordance with a direction given to the Chair to vote on the Resolutions as the Chair decides; or
- (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolutions; and
 - (ii) the holder votes on the Resolutions in accordance with directions given by the beneficiary to the holder to vote in that way.

Voting Prohibition Statement

In accordance with section 224 of the Corporations Act, a vote on these Resolutions must not be cast (in any capacity) by or on behalf of a related party to whom Resolutions 5(a) – 5(b) would permit a financial benefit to be given or an associate of such related party (**Resolutions 5(a) – 5(b) Excluded Party**). However, this prohibition does not apply if the vote is cast by a person as proxy appointed by writing that specifies how the proxy is to vote on the Resolutions and is not cast on behalf of a Resolutions 5(a) – 5(b) Excluded Party.

6. Resolution 6 – Approval of 10% Placement Facility (under ASX Listing Rule 7.1A)

To consider, and, if thought fit, to pass with or without amendment, as a **special resolution**, the following:

“That, pursuant to and in accordance with ASX Listing Rule 7.1A and for all other purposes, the Shareholders approve the issue of Equity Securities up to 10% of the issued capital of the Company (at the time of issue) calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 and on the terms and conditions set out in the Explanatory Memorandum.”

7. Resolution 7 – Approval of change of Auditor

To consider, and, if thought fit, to pass with or without amendment, as an **ordinary resolution**, the following:

“That, for the purposes of section 327B(1)(b) of the Corporations Act and for all other purposes, and subject to the consent from ASIC to the current auditor resigning, RSM Australia Partners, having been nominated by a Shareholder and having consented in writing to act in the capacity of auditor, be appointed as auditor of the Company with effect from the Effective Date.”

Dated 30 October 2026

BY ORDER OF THE BOARD

Johnathon Busing
Company Secretary
Patrys Limited

EXPLANATORY MEMORANDUM

1. Introduction

This Explanatory Memorandum has been prepared for the information of Shareholders of the Company in connection with the business to be conducted at the Meeting to be held in person at Level 2, 7 Havelock Street, West Perth, Western Australia 6005 on Monday, 30 November 2026, commencing at 1:00pm AWST.

This Explanatory Memorandum should be read in conjunction with, and forms part of, the accompanying Notice. The purpose of this Explanatory Memorandum is to provide information to Shareholders in deciding whether or not to pass the Resolutions in the Notice.

A Proxy Form is located at the end of the Explanatory Memorandum.

2. Action to be taken by Shareholders

Shareholders should read the Notice and this Explanatory Memorandum carefully before deciding how to vote on the Resolutions.

2.1 Proxies

A Proxy Form is attached to the Notice. This is to be used by Shareholders if they wish to appoint a representative (a proxy) to vote in their place. All Shareholders are invited and encouraged to participate in the Meeting and are encouraged to lodge a directed Proxy Form with the Company in accordance with the instructions thereon. Lodgement of a Proxy Form will not preclude a Shareholder from attending and voting at the Meeting in person. Proxy Forms must be received by 1:00pm (AWST) on Saturday, 28 November 2026.

Please note that:

- (a) a member of the Company entitled to vote at the Meeting is entitled to appoint a proxy;
- (b) a proxy need not be a member of the Company; and
- (c) a member of the Company entitled to cast two or more votes may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise, but where the proportion or number is not specified, each proxy may exercise half of the votes.

Shareholders and their proxies should be aware that:

- (a) if proxy holders vote, they must cast all directed proxies as they are directed to; and
- (b) any directed proxies which are not voted will automatically default to the Chair, who must vote the proxies as directed.

Further details are set out below.

Proxy vote if appointment specifies way to vote

Section 250BB(1) of the Corporations Act provides that an appointment of a proxy may specify the way the proxy is to vote on a particular resolution and, if it does:

- (a) the proxy need not vote on a show of hands, but if the proxy does so, the proxy must vote that way (i.e., as directed); and

- (b) if the proxy has 2 or more appointments that specify different ways to vote on the resolution – the proxy must not vote on a show of hands; and
- (c) if the proxy is the Chair of the meeting at which the resolution is voted on – the proxy must vote on a poll, and must vote that way (i.e., as directed); and
- (d) if the proxy is not the Chair – the proxy need not vote on the poll, but if the proxy does so, the proxy must vote that way (i.e., as directed).

Transfer of non-chair proxy to Chair in certain circumstances

Section 250BC of the Corporations Act provides that, if:

- (a) an appointment of a proxy specifies the way the proxy is to vote on a particular resolution at a meeting of the Company's members; and
- (b) the appointed proxy is not the Chair of the meeting; and
- (c) at the meeting, a poll is duly demanded, or is otherwise required under section 250JA, on the question that the resolution be passed; and
- (d) either of the following applies:
 - (i) if a record of attendance is made for the meeting – the proxy is not recorded as attending; or
 - (ii) the proxy does not vote on the resolution,

the Chair of the meeting is taken, before voting on the resolution closes, to have been appointed as the proxy for the purposes of voting on the resolution at the meeting.

The enclosed Proxy Form provides further details on appointing proxies and lodging Proxy Forms.

2.2 Proxy Holders and Voting Instructions

If the Chair is appointed as your proxy and the Chair is not directed how to vote, you are authorising the Chair to cast your undirected vote on all proposed resolutions.

If a member of the Company's Key Management Personnel, or a Closely Related Party of such member, is appointed as your proxy, they will not be able to vote your proxy on Resolution 1, Resolution 5(a) and Resolution 5(b), unless you direct them how to do so.

If you intend to appoint a member of the Company's Key Management Personnel, or a Closely Related Party of such member, or the Chair, as your proxy, you are encouraged to direct them how to vote on Resolution 1, Resolution 5(a) and Resolution 5(b), by marking "For", "Against" or "Abstain" for each of those Resolutions.

2.3 Submit your Proxy Vote

2.3.1 Online

Vote online at <https://investor.automic.com.au/#/loginsah> and simply follow the instructions on the enclosed Proxy Form.

2.3.2 By Paper

If you do not wish to vote online, then it is necessary to complete the Proxy Form in accordance with the detailed instructions set out on the enclosed Proxy Form.

The return of your completed form (ONLY if you do NOT vote online) can be done in one of the following ways:

BY MAIL	Automic GPO Box 5193 Sydney, New South Wales 2001
BY EMAIL	meetings@automicgroup.com.au
BY FAX	+61 (2) 8583 3040

3. Annual Report

There is no requirement for Shareholders to approve the Annual Report.

Shareholders will be offered the following opportunities:

- (a) to discuss the Annual Report which is available online at <https://www.patrys.com>;
- (b) to ask questions or make comments on the management of the Company; and
- (c) to ask the auditor questions about the conduct of the audit and the preparation and content of the Auditor's Report.

In addition to taking questions at the Meeting, written questions to the Chair about the management of the Company, or to the Company's auditor about:

- (a) the preparation and the content of the Auditor's Report;
- (b) the conduct of the audit;
- (c) accounting policies adopted by the Company in relation to the preparation of the financial statements; and
- (d) the independence of the auditor in relation to the conduct of the audit,

may be submitted no later than five (5) Business Days before the Meeting (being Monday, 23 November 2026) to the Company Secretary at the Company's registered office.

4. Resolution 1 – Adoption of Remuneration Report

Section 250R(2) of the Corporations Act provides that the Company is required to put the Remuneration Report to the vote of Shareholders. The Directors' Report contains the Remuneration Report which sets out the remuneration policy for the Company and reports the remuneration arrangements in place for the executive Directors, specified executives and non-executive Directors.

Section 250R(3) of the Corporations Act provides that Resolution 1 is advisory only and does not bind the Directors of the Company. Of itself, a failure of Shareholders to pass Resolution 1 will not require the Directors to alter any of the arrangements in the Remuneration Report.

However, the Corporations Act also gives Shareholders the opportunity to remove the Board if the Remuneration Report receives a 'no' vote of 25% or more at two consecutive annual general meetings (**Two Strikes Rule**).

Under the Two Strikes Rule, where a resolution on the Remuneration Report receives a 'no' vote of 25% or more at two consecutive annual general meetings, the Company will be required to put to Shareholders at the second annual general meeting a resolution on whether another meeting should be held (within 90 days) at which all Directors (other than the managing director) who were in office at the date of approval of the applicable Directors' Report will cease to hold office immediately before that further meeting but may stand for re-election.

At the Company's previous annual general meeting held on 9 October 2025, the votes cast against the Remuneration Report considered at that annual general meeting were less than 25%. Accordingly, a further resolution relating to the Two Strikes Rule is not relevant for this Annual General Meeting.

The Chair will allow a reasonable opportunity for Shareholders (as a whole) to ask about, or make comments on, the Remuneration Report.

The Chair intends to exercise all undirected proxies in favour of Resolution 1. If the Chair of the Meeting is appointed as your proxy and you have not specified the way the Chair is to vote on Resolution 1, by signing and returning the Proxy Form, you are considered to have provided the Chair with an express authorisation for the Chair to vote the proxy in accordance with the Chair's intention.

5. Resolution 2 – Election of Director – Mr Dino Cercarelli

5.1 General

Clause 15.1(c) of the Constitution provides that the Directors may at any time appoint any person to be a Director.

ASX Listing Rule 14.4 provides that a director appointed to fill a casual vacancy or as an addition to the board must not hold office (without re-election) past the next annual general meeting of the entity.

Mr Dino Cercarelli (**Mr Cercarelli**), having been appointed to the Board on 28 January 2026 to fill a casual vacancy, will retire in accordance with clause 15.1(c) of the Constitution and ASX Listing Rule 14.4 and, being eligible, seeks election.

5.2 Background and qualifications

Mr Cercarelli is a healthcare and clinical research executive with more than 20 years' experience in clinical trial operations, research governance, organisational leadership and healthcare management. He is currently Business and Operations Manager of the Perth Children's Trials Centre at Perth Children's Hospital, where he leads the Centre's development, operations and strategic direction.

Mr Cercarelli previously served as Chief Operating Officer of the Australian Clinical Trials Alliance and spent eight years with St John of God Health Care leading research and clinical trial operations. He was also a co-founder and Managing Director of Reliis Pty Ltd, which the Company acquired on 28 January 2026.

Mr Cercarelli holds a Master of Business Administration and postgraduate qualifications in business and health services management.

5.3 Independence

If elected, the Board considers Mr Cercarelli to be an independent Director.

5.4 Board recommendation

The Board (excluding Mr Cercarelli) recommends that Shareholders vote in favour of Resolution 2. The Chair of the Meeting intends to vote undirected proxies in favour of Resolution 2.

6. Resolution 3 – Election of Director – Ms Leanne Kite

6.1 General

Clause 15.1(c) of the Constitution provides that the Directors may at any time appoint any person to be a Director.

ASX Listing Rule 14.4 provides that a director appointed to fill a casual vacancy or as an addition to the board must not hold office (without re-election) past the next annual general meeting of the entity.

Ms Leanne Kite (**Ms Kite**), having been appointed to the Board on 28 January 2026 to fill a casual vacancy, will retire in accordance with clause 15.1(c) of the Constitution and ASX Listing Rule 14.4 and, being eligible, seeks election.

6.2 Background and qualifications

Ms Kite, a Chartered Accountant, is a finance, governance and investor relations executive with more than 20 years' experience across the biotechnology, resources and energy sectors. As a co-founder of Reliis Pty Ltd, which the Company acquired on 28 January 2026, she contributed extensive expertise in financial management, corporate governance, strategy and investor relations.

Her professional background includes 13 years in senior finance, strategy and commercial roles at Woodside Energy (ASX: WDS) and leading investor relations for Lontown Limited (ASX: LTR). Ms Kite is currently an Executive Director, Chief Financial Officer and Company Secretary of Elk Range Mining Limited (ASX: ELK).

She holds a Bachelor of Commerce and a Graduate Diploma in Investor Relations, and is a Fellow of the Governance Institute of Australia, a qualified Company Secretary and a graduate of the Australian Institute of Company Directors.

6.3 Independence

If elected, the Board considers Ms Kite to be an independent Director.

6.4 Board recommendation

The Board (excluding Ms Kite) recommends that Shareholders vote in favour of Resolution 3. The Chair of the Meeting intends to vote undirected proxies in favour of Resolution 3.

7. Resolution 4 – Election of Director – Mr Brian Leedman

7.1 General

Clause 15.1(c) of the Constitution provides that the Directors may at any time appoint any person to be a Director.

ASX Listing Rule 14.4 provides that a director appointed to fill a casual vacancy or as an addition to the board must not hold office (without re-election) past the next annual general meeting of the entity.

Mr Brian Leedman (**Mr Leedman**), having been appointed to the Board on 10 November 2025 to fill a casual vacancy, will retire in accordance with clause 15.1(c) of the Constitution and ASX Listing Rule 14.4 and, being eligible, seeks election.

7.2 Background and qualifications

Mr Leedman is an experienced biotechnology executive and company director with more than 20 years' experience in corporate strategy, investor relations and capital markets within the life sciences sector. He is the founder and former director of ResApp Health Ltd, which was acquired by Pfizer Inc. in 2022, and has held board roles across a number of ASX-listed biotechnology companies, including NeuroScientific Biopharmaceuticals Ltd (ASX: NSB), Neurotech International Limited (ASX: NTI), Alcidion Corporation, OncoSil Medical Ltd (ASX: OSL) and Respi Limited.

Mr Leedman is currently Non-Executive Chair of BlinkLab Limited (ASX: BB1) and has experience supporting emerging biomedical companies through research, clinical development and commercialisation. He holds a Bachelor of Economics and a Master of Business Administration from the University of Western Australia.

7.3 Independence

If elected, the Board considers Mr Leedman to be an independent Director.

7.4 Board recommendation

The Board (excluding Mr Leedman) recommends that Shareholders vote in favour of Resolution 4. The Chair of the Meeting intends to vote undirected proxies in favour of Resolution 4.

8. Resolutions 5(a) and 5(b) – Approval to issue Director Placement Securities to Mr Brian Leedman (under ASX Listing Rule 10.11)

8.1 General

On 20 April 2026, the Company announced that it had received binding commitments from sophisticated and professional investors (**Placement Participants**) for a placement to raise up to approximately \$3,200,000 (before costs), via the issue of up to 133,333,333 Shares at an issue price of \$0.024 per Share (**Placement Shares**), together with one (1) free-attaching Option (exercisable at \$0.048 and expiring on 30 November 2030) (**Placement Options**) for every four (4) Placement Shares subscribed for and issued (**Placement**).

At the general meeting held on 8 June 2026 (**General Meeting**), the Company obtained shareholder approval for Director participation under the Placement. On 8 June 2026, the

Company announced that due to an administrative oversight, the notice of meeting for the General Meeting did not include resolutions for Mr Brian Leedman's participation in the Placement.

Accordingly, Resolutions 5(a) and (b) seek Shareholder approval under ASX Listing Rule 10.11 for the issue of:

- (a) 2,083,333 Placement Shares (**Director Placement Shares**) (being the subject of Resolution 5(a)); and
- (b) 520,833 Placement Options (**Director Placement Options**) (being the subject of Resolution 5(b)),

(together, the **Director Placement Securities**), to Mr Brian Leedman (and/or his nominees).

Further details regarding the Placement are set out in the Company's announcement dated 20 April 2026.

8.2 Chapter 2E of the Corporations Act

For a public company, or an entity that the public company controls, to give a financial benefit to a related party of the public company, the public company or entity must:

- (a) obtain the approval of the public company's members in the manner set out in sections 217 to 227 of the Corporations Act; and
- (b) give the benefit within 15 months following such approval,

unless the giving of the financial benefit falls within an exception set out in sections 210 to 216 of the Corporations Act.

The issue of the Director Placement Securities constitutes giving a financial benefit to Mr Leedman (and/or his nominee(s)), who is a related party of the Company by virtue of being a Director.

The Directors (other than Mr Leedman, who has a material personal interest in Resolutions 5(a) and 5(b)) consider that Shareholder approval under Chapter 2E of the Corporations Act is not required, because the Director Placement Securities will be issued on the same terms as the Placement Shares and Placement Options issued to the unrelated Placement Participants. The giving of the financial benefit is therefore on arm's length terms for the purposes of section 210 of the Corporations Act.

8.3 ASX Listing Rule 10.11

ASX Listing Rule 10.11 provides that unless one of the exceptions in ASX Listing Rule 10.12 applies, a listed company must not issue or agree to issue Equity Securities to:

- (a) a related party;
- (b) a person who is, or was at any time in the six (6) months before the issue or agreement, a substantial (30%+) holder in the company;
- (c) a person who is, or was at any time in the six (6) months before the issue or agreement, a substantial (10%+) holder in the company and who has nominated a director to the board of the company pursuant to a relevant agreement which gives them a right or expectation to do so;
- (d) an associate of a person referred to in ASX Listing Rules 10.11.1 to 10.11.3; or

- (e) a person whose relationship with the company or a person referred to in ASX Listing Rules 10.11.1 to 10.11.4 is such that, in ASX's opinion, the issue or agreement should be approved by its shareholders,

unless it obtains the approval of its shareholders.

The proposed issue of the Director Placement Securities falls within ASX Listing Rule 10.11.1 and does not fall within any of the exceptions in ASX Listing Rule 10.12. Accordingly, the proposed issue of the Director Placement Securities requires the approval of Shareholders under ASX Listing Rule 10.11.

Resolutions 5(a) and 5(b) seek the required Shareholder approval for the proposed issue of the Director Placement Securities for the purposes of ASX Listing Rule 10.11.

8.4 Technical information required by ASX Listing Rule 14.1A

If Resolutions 5(a) and 5(b) are passed, the Company will be able to proceed with the issue of the Director Placement Securities within one (1) month after the date of the Meeting (or such later date as permitted by any ASX waiver or modification of the ASX Listing Rules). As approval pursuant to ASX Listing Rule 7.1 is not required for the issue of the Director Placement Securities (because approval is being obtained under ASX Listing Rule 10.11), the issue of the Director Placement Securities will not use up any of the Company's 15% placement capacity under ASX Listing Rule 7.1.

If Resolutions 5(a) and 5(b) are not passed, the Company will not be able to proceed with the issue of the Director Placement Securities, and no further funds will be raised in respect of Mr Leedman's participation in the Placement.

8.5 Technical information required by ASX Listing Rule 10.13

Pursuant to and in accordance with ASX Listing Rule 10.13, the following information is provided in relation to Resolutions 5(a) and 5(b):

- (a) the Director Placement Securities will be issued to Mr Brian Leedman (and/or his nominee(s)), who falls within the category set out in ASX Listing Rule 10.11.1 by virtue of being a Director;
- (b) a total of 2,083,333 Director Placement Shares and 520,833 Director Placement Options are to be issued to Mr Leedman (and/or his nominee(s));
- (c) the Director Placement Shares will be fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares;
- (d) the terms and conditions of the Director Placement Options are set out in Schedule 3;
- (e) the Director Placement Securities will be issued no later than one (1) month after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the ASX Listing Rules) and it is intended that the issue will occur on the same date;
- (f) the Director Placement Shares will be issued at \$0.024 each, being the same issue price as the Placement Shares issued to the unrelated Placement Participants, and the Director Placement Options will be issued for nil cash consideration as they are free-attaching to the Director Placement Shares on a one (1) for four (4) basis;
- (g) the purpose of the issue of the Director Placement Shares is to allow Mr Leedman to participate in the Placement on the same terms as the unrelated Placement Participants and to raise approximately \$50,000 (before costs). The funds raised will be aggregated with the funds raised via the issue of Placement Shares, and applied for the same purposes as

the funds raised under the Placement, as set out in in the Company's announcement dated 20 April 2026;

- (h) the issue of the Director Placement Securities is not intended to remunerate or incentivise Mr Leedman;
- (i) the Director Placement Securities are not being issued under an agreement; and
- (j) a voting exclusion statement is included in Resolutions 5(a) and 5(b) of the Notice.

8.6 Board recommendation

The Directors (other than Mr Leedman, who has a material personal interest in Resolutions 5(a) and 5(b)) believe Resolutions 5(a) and 5(b) are in the best interests of the Company and its Shareholders and unanimously recommend that Shareholders vote in favour of Resolutions 5(a) and 5(b). The Chair intends to vote undirected proxies in favour of Resolutions 5(a) and 5(b).

9. Resolution 6 – Approval of 10% Placement Facility (under ASX Listing Rule 7.1A)

9.1 General

ASX Listing Rule 7.1A enables eligible entities to issue Equity Securities up to 10% of their issued share capital through placements commencing from the date of the Meeting where the Company obtains the approval until the earlier of the following:

- (a) the date that is 12 months after the date of the Meeting at which the approval is obtained;
- (b) the time and date of the Company's next annual general meeting; or
- (c) the time and date of the approval of Shareholders of a transaction under ASX Listing Rule 11.1.2 or 11.2 in respect of the Company,

(10% Placement Facility).

The 10% Placement Facility is in addition to the Company's 15% placement capacity under ASX Listing Rule 7.1.

An eligible entity for the purposes of ASX Listing Rule 7.1A is an entity that is not included in the S&P/ASX 300 Index and has a market capitalisation of \$300 million or less. The Company currently has a market capitalisation of approximately \$18,220,823 (based on the total number of Shares on issue and the closing price of Shares on ASX as at 19 October 2026) and is therefore an eligible entity.

The Company is now seeking Shareholder approval by way of a special resolution to have the ability to issue Equity Securities under the 10% Placement Facility.

The exact number of Equity Securities to be issued under the 10% Placement Facility will be determined in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 (refer to Section 9.2(c) below).

9.2 Description of ASX Listing Rule 7.1A

(a) Shareholder approval

The ability to issue Equity Securities under the 10% Placement Facility is subject to Shareholder approval by way of a special resolution at an annual general meeting. Accordingly, at least 75% of votes cast by Shareholders present and eligible to vote at the Meeting must be in favour of Resolution 6 for it to be passed.

(b) Equity Securities

Any Equity Securities issued under the 10% Placement Facility must be in the same class as an existing quoted class of Equity Securities of the Company.

The Company, as at the date of the Notice, has on issue one class of quoted Equity Securities, being Shares (ASX: PAB).

(c) Formula for calculating 10% Placement Facility

ASX Listing Rule 7.1A.2 provides that eligible entities which have obtained shareholder approval at an annual general meeting may issue or agree to issue, during the 12-month period after the annual general meeting, a number of Equity Securities calculated in accordance with the following formula:

$$(A \times D) - E$$

Where:

A is the number of fully paid ordinary securities on issue at the commencement of the relevant period:

- (A) plus the number of fully paid ordinary securities issued in the relevant period under an exception in ASX Listing Rule 7.2 other than Exception 9, 16 or 17;
- (B) plus the number of fully paid ordinary securities issued in the relevant period on the conversion of convertible securities within ASX Listing Rule 7.2 Exception 9 where:
 - (1) the convertible securities were issued or agreed to be issued before the commencement of the relevant period; or
 - (2) the issue of, or agreement to issue, the convertible securities was approved, or taken to have been approved, under ASX Listing Rule 7.1 or 7.4;
- (C) plus the number of fully paid ordinary securities issued in the relevant period under an agreement to issue securities within ASX Listing Rule 7.2 Exception 16 where:
 - (1) the agreement was entered into before the commencement of the relevant period; or
 - (2) the agreement or issue was approved, or taken under these rules to have been approved, under ASX Listing Rule 7.1 or 7.4;
- (D) plus the number of any other fully paid ordinary securities issued in the relevant period with approval under ASX Listing Rule 7.1 or 7.4;

- (E) plus the number of partly paid ordinary securities that became fully paid in the relevant period;
- (F) less the number of fully paid shares cancelled in the relevant period.

Note that "A" has the same meaning in ASX Listing Rule 7.1 when calculating an entity's 15% placement capacity.

D is 10%.

E is the number of Equity Securities issued or agreed to be issued under ASX Listing Rule 7.1A.2 in the relevant period where the issue or agreement has not been subsequently approved by the holders of its ordinary securities under ASX Listing Rule 7.4.

(d) ASX Listing Rule 7.1 and ASX Listing Rule 7.1A

The ability of an entity to issue Equity Securities under ASX Listing Rule 7.1A is in addition to the entity's 15% placement capacity under ASX Listing Rule 7.1.

At the date of this Notice, the Company has on issue 674,845,324 Shares and therefore has the capacity to issue:

- (i) 101,226,798 Equity Securities under ASX Listing Rule 7.1; and
- (ii) 67,484,532 Equity Securities under ASX Listing Rule 7.1A (subject to Resolution 6 being passed).

The actual number of Equity Securities that the Company will have capacity to issue under ASX Listing Rule 7.1A will be calculated at the date of issue of the Equity Securities in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 (refer to Section 9.2(c) above).

(e) Minimum Issue Price

The issue price of Equity Securities issued under ASX Listing Rule 7.1A must be not less than 75% of the VWAP of Equity Securities in the same class calculated over the 15 Trading Days on which trades in that class were recorded immediately before:

- (i) the date on which the price at which the Equity Securities are to be issued is agreed; or
- (ii) if the Equity Securities are not issued within 10 Trading Days of the date in paragraph (i) above, the date on which the Equity Securities are issued.

(f) 10% Placement Period

Shareholder approval of the 10% Placement Facility under ASX Listing Rule 7.1A is valid from the date of the Meeting at which the approval is obtained and expires on the earlier to occur of:

- (i) the date that is 12 months after the date of the Meeting at which the approval is obtained;
- (ii) the time and date of the entity's next annual general meeting; or
- (iii) the time and date of the approval by shareholders of the eligible entity's ordinary securities of a transaction under ASX Listing Rules 11.1.2 (a

significant change to the nature or scale of activities) or 11.2 (disposal of main undertaking),

(10% Placement Period).

9.3 ASX Listing Rule 7.1A

The effect of Resolution 6 will be to allow the Directors to issue the Equity Securities under ASX Listing Rule 7.1A during the 10% Placement Period without using the Company's 15% placement capacity under ASX Listing Rule 7.1.

Resolution 6 is a special resolution and therefore requires approval of at least 75% of the votes cast by Shareholders present and eligible to vote (in person, by proxy, by attorney or, in the case of a corporate Shareholder, by a corporate representative) on this Resolution 6.

9.4 Specific information required by ASX Listing Rule 7.3A

Pursuant to and in accordance with ASX Listing Rule 7.3A, information is provided in relation to the approval of the 10% Placement Facility as follows:

- (a) The Equity Securities will be issued at an issue price of not less than 75% of the VWAP for the Company's Equity Securities over the 15 Trading Days on which trades in that class were recorded immediately before:
 - (i) the date on which the price at which the Equity Securities are to be issued is agreed; or
 - (ii) if the Equity Securities are not issued within 10 Trading Days of the date in paragraph (i) above, the date on which the Equity Securities are issued.
- (b) If Resolution 6 is approved by Shareholders and the Company issues Equity Securities under the 10% Placement Facility, the existing Shareholders' voting power in the Company will be diluted as shown in the below table. There is a risk that:
 - (i) the market price for the Company's Equity Securities in that class may be significantly lower on the date of the issue of the Equity Securities than on the date of the Meeting; and
 - (ii) the Equity Securities may be issued at a price that is at a discount to the market price for the Company's Equity Securities on the issue date,

which may have an effect on the amount of funds raised by the issue of the Equity Securities.

The below table shows the dilution of existing Shareholders on the basis of the current market price of Shares and the current number of ordinary securities for variable "A" calculated in accordance with the formula in ASX Listing Rule 7.1A.2 as at the date of this Notice.

The table shows:

- (i) two examples where variable "A" has increased, by 50% and 100%. Variable "A" is based on the number of ordinary securities the Company has on issue. The number of ordinary securities on issue may increase as a result of issues of ordinary securities that do not require Shareholder approval (for example, a pro rata entitlements issue or scrip issued under a takeover offer) or future specific placements under ASX Listing Rule 7.1 that are approved at a future Shareholders' meeting; and

- (ii) two examples where the issue price of ordinary securities has decreased by 50% and increased by 100% as against the current market price.

Variable "A" in ASX Listing Rule 7.1A.2		Dilution		
		\$0.0135 50% decrease in Issue Price	\$0.027 Issue Price	\$0.054 100% increase in Issue Price
Current Variable "A" 674,845,324 Shares	10% Voting Dilution	67,484,532 Shares	67,484,532 Shares	67,484,532 Shares
	Funds raised	\$911,041	\$1,822,082	\$3,644,165
50% increase in current Variable "A" 1,012,267,986 Shares	10% Voting Dilution	101,226,799 Shares	101,226,799 Shares	101,226,799 Shares
	Funds raised	\$1,366,562	\$2,733,124	\$5,466,247
100% increase in current Variable "A" 1,349,690,648 Shares	10% Voting Dilution	134,969,065 Shares	134,969,065 Shares	134,969,065 Shares
	Funds raised	\$1,822,082	\$3,644,165	\$7,288,330

Note

The table has been prepared on the following assumptions:

1. The Company issues the maximum number of Equity Securities available under the 10% Placement Facility.
2. No Options (including any Options issued under the 10% Placement Facility) are exercised into Shares before the date of the issue of the Equity Securities.
3. The 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example at 10%.
4. The table does not show an example of dilution that may be caused to a particular Shareholder by reason of placements under the 10% Placement Facility, based on the Shareholder's holding at the date of the Meeting.
5. The table shows only the effect of issue of Equity Securities under ASX Listing Rule 7.1A, not under the 15% placement capacity under ASX Listing Rule 7.1.
6. The issue of Equity Securities under the 10% Placement Facility consists only of Shares.
7. The issue price is \$0.027, being the closing price of the Shares on ASX on 19 October 2026.

- (c) The Company will only issue and allot the Equity Securities during the 10% Placement Period. The approval under Resolution 6 for the issue of the Equity Securities will cease to be valid in the event that Shareholders approve a transaction under ASX Listing Rule 11.1.2 (a significant change to the nature or scale of activities) or 11.2 (disposal of main undertaking).
- (d) The Company can only issue Equity Securities for cash consideration. In such circumstances, the Company intends to use the funds raised towards the continued clinical development of RLS-2202, an acquisition of new assets or investments (including expenses associated with such acquisition) and general working capital.
- (e) The Company will comply with the disclosure obligations under ASX Listing Rule 7.1A.4 upon issue of any Equity Securities.

- (f) The Company's allocation policy is dependent on the prevailing market conditions at the time of any proposed issue pursuant to the 10% Placement Facility. The identity of the allottees of the Equity Securities will be determined on a case-by-case basis having regard to factors including but not limited to the following:
- (i) the methods of raising funds that are available to the Company, including but not limited to a rights issue or other issue in which existing security holders can participate;
 - (ii) the effect of the issue of the Equity Securities on the control of the Company;
 - (iii) the financial situation and solvency of the Company; and
 - (iv) advice from corporate, financial and broking advisers (if applicable).

The allottees under the 10% Placement Facility have not been determined as at the date of this Notice but may include existing substantial Shareholders and/or new Shareholders who are not Related Parties or Associates of a Related Party of the Company.

- (g) The Company previously obtained Shareholder approval under ASX Listing Rule 7.1A at its annual general meeting held on 9 October 2025. In the 12 months preceding the date of the 2026 Annual General Meeting, the Company issued or agreed to issue a total of 50,941,575 Equity Securities under ASX Listing Rule 7.1A.2, representing 16%¹ of the total number of Equity Securities on issue at 9 October 2025. Details of each issue are set out in Schedule 2.
- (h) For the purpose of ASX Listing Rule 14.1A (and in addition to the disclosure in Section 9.4(b) above):
- (i) if Resolution 6 is passed, the Directors will be able to issue the Equity Securities under ASX Listing Rule 7.1A during the 10% Placement Period without using the Company's 15% placement capacity under ASX Listing Rule 7.1; and
 - (ii) if Resolution 6 is not passed, the Directors will not be able to issue the Equity Securities under ASX Listing Rule 7.1A, and will have to either rely on the Company's existing 15% placement capacity under ASX Listing Rule 7.1 (from time to time), or (in the event that the Company's 15% placement capacity is exhausted) the Company will be required to obtain prior Shareholder approval under ASX Listing Rule 7.1 before being able to issue such Equity Securities (which may result in the Company incurring further time and expense).

As at the date of this Notice, the Company is not proposing to make an issue of Equity Securities under ASX Listing Rule 7.1A.2 and has not approached any particular existing Shareholder or security holder or an identifiable class of existing security holder to participate in an issue of Equity Securities under ASX Listing Rule 7.1A.2. Accordingly, a voting exclusion statement is not included in this Notice.

9.5 Board recommendation

The Directors of the Company believe Resolution 6 is in the best interests of the Company and its Shareholders and unanimously recommend that the Shareholders vote in favour of

¹ The Company issued additional Equity Securities subsequent to obtaining Shareholder approval under Listing Rule 7.1A on 9 October 2025. Accordingly, the 16% figure above is calculated by reference to the number of Equity Securities on issue as at 9 October 2025 and does not represent 16% of the Company's current issued capital.

this Resolution. The Chair of the Meeting intends to vote undirected proxies in favour of Resolution 6.

10. Resolution 7 – Approval of change of auditor

10.1 General

The Board has resolved to propose the appointment of RSM Australia Partners (**RSM**) as the Company's auditor. As a consequence, BDO Audit Pty Ltd (**BDO**) has given notice of its intention to resign as auditor of the Company to ASIC under section 329(5) of the Corporations Act.

As at the date of this Notice, ASIC has not provided its consent. Upon receipt of ASIC's consent to the resignation, BDO has advised that it will submit a notice of resignation to the Company in accordance with section 329(5) of the Corporations Act, with such resignation to take effect from the later of:

- (a) the date of receipt of ASIC's consent to the resignation;
- (b) the date fixed by ASIC; or
- (c) the date of this Meeting (subject to Shareholders approving this Resolution 7),

(Effective Date).

In accordance with section 328B(1) of the Corporations Act, the Company has sought and obtained a nomination from a Shareholder for RSM to be appointed as the Company's auditor. A copy of this nomination is included at Schedule 4.

RSM has given its written consent to act as the Company's auditor, subject to ASIC consenting to the resignation of BDO.

If this Resolution 7 (which is an ordinary resolution) is passed, the appointment of RSM as the Company's auditor will take effect from the Effective Date.

10.2 Recommendation of the Board

The Directors of the Company believe Resolution 7 is in the best interest of the Company and its Shareholders and unanimously recommend that the Shareholders vote in favour of this Resolution. The Chair intends to vote all undirected proxies in favour of this Resolution 7.

SCHEDULE 1– Definitions

In this Notice and the Explanatory Memorandum:

\$ means Australian dollars.

10% Placement Facility has the meaning given to that phrase in Section 9.1.

10% Placement Period has the meaning given to that phrase in Section 9.2(f).

Annual Report means the Directors' Report, the Financial Report and the Auditor's Report in respect of the financial year ended 30 June 2026.

ASIC means the Australian Securities and Investments Commission.

Associate has the meaning given in sections 12 and 16 of the Corporations Act. Section 12 is to be applied as if paragraph 12(1)(a) included a reference to the ASX Listing Rules and on the basis that the Company is the "designated body" for the purposes of that section. A related party of a director or officer of the Company or of a Child Entity of the Company is to be taken to be an associate of the director or officer unless the contrary is established.

ASX means ASX Limited (ACN 008 624 691) and, where the context permits, the Australian Securities Exchange operated by ASX.

ASX Listing Rules or **Listing Rules** means the listing rules of the ASX.

Auditor's Report means the auditor's report on the Financial Report.

AWST means Australian Western Standard Time, being the time in Perth, Western Australia.

BDO has the meaning given to that term in Section 10.1.

Board means the board of Directors.

Business Day means:

- (a) for determining when a notice, consent or other communication is given, a day that is not a Saturday, Sunday or public holiday in the place to which the notice, consent or other communication is sent; and
- (b) for any other purpose, a day (other than a Saturday, Sunday or public holiday) on which banks are open for general banking business in Perth.

Chair means the person appointed to chair the Meeting convened by this Notice.

Child Entity has the meaning given in the ASX Listing Rules.

Closely Related Party of a member of the Key Management Personnel means:

- (a) a spouse or child of the member; or
- (b) any other person within the meaning given in section 9 of the Corporations Act.

Company means Patrys Limited (ACN 123 055 363).

Company Secretary means the company secretary of the Company.

Constitution means the constitution of the Company as at the commencement of the Meeting.

Corporations Act means the *Corporations Act 2001* (Cth).

Director means a director of the Company.

Director Placement Options has the meaning given to that term in Section 8.1.

Director Placement Securities has the meaning given to that term in Section 8.1.

Director Placement Shares has the meaning given to that term in Section 8.1.

Directors' Report means the annual directors' report prepared under Chapter 2M of the Corporations Act for the Company and its controlled entities contained in the Annual Report.

Effective Date has the meaning given to that phrase in Section 10.1.

Equity Securities has the meaning given to that phrase in the ASX Listing Rules.

Explanatory Memorandum means the explanatory memorandum attached to the Notice.

Financial Report means the annual financial report prepared under Chapter 2M of the Corporations Act of the Company and its controlled entities.

General Meeting has the meaning given to that term in Section 8.1.

Key Management Personnel means persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) of the Company.

Meeting or **Annual General Meeting** has the meaning given in the introductory paragraph of the Notice.

Mr Cercarelli has the meaning given to that term in Section 5.1.

Mr Leedman has the meaning given to that term in Section 7.1.

Ms Kite has the meaning given to that term in Section 6.1.

Notice means this notice of meeting.

Option means an option which entitles the holder to subscribe for one Share.

Placement has the meaning given to that term in Section 8.1.

Placement Options has the meaning given to that term in Section 8.1.

Placement Participants has the meaning given to that term in Section 8.1.

Placement Shares has the meaning given to that term in Section 8.1.

Proxy Form means the proxy form attached to the Notice.

Related Party has the meaning given to that phrase in:

- (a) chapter 19 of the ASX Listing Rules; or
- (b) section 9 of the Corporations Act.

Remuneration Report means the remuneration report of the Company contained in the Directors' Report.

Resolution means a resolution contained in the Notice.

RSM has the meaning given to that term in Section 10.1.

Schedule means a schedule to this Notice.

Section means a section contained in this Explanatory Memorandum.

Share means a fully paid ordinary share in the capital of the Company.

Shareholder means a shareholder of the Company.

Trading Day means a day determined by ASX to be a trading day in accordance with the ASX Listing Rules.

Two Strikes Rule has the meaning given to that phrase in Section 4.

VWAP means volume weighted average price.

In this Notice and the Explanatory Memorandum words importing the singular include the plural and vice versa.

SCHEDULE 2 – Equity Securities Issued under Listing Rule 7.1A in 12-months preceding the Annual General Meeting

Date of issue	Number issued	Class/Type of equity security and Summary of terms	Names of persons who received securities or basis on which those persons were determined	Issue Price and discount	Rule pursuant to which the Issue is made	Consideration	
29 April 2026	50,941,575 Shares	Fully paid ordinary Share issued on the same terms and conditions as the ordinary Shares in the Company	The fully paid ordinary shares were issued to: sophisticated and professional investors as part of a private Placement.	Issue Price: \$0.024 Discount: 22.58% discount to market price at the time of issue.	50,941,575 Fully paid ordinary shares issued pursuant to ASX Listing Rule 7.1A.	Total cash consideration	\$1,222,598
						Amount of cash consideration spent and Description of what consideration was spent on	NIL
						Amount of cash consideration remaining and Intended use for remaining cash consideration	\$1,222,598 Intended use of remaining funds: The funds will be directed towards continued clinical development of RLS-2202, an acquisition of new assets or investments (including expenses associated with such acquisition) and general working capital.
						Non-cash consideration paid and current value of that non-cash consideration	

SCHEDULE 3 – Terms and Conditions of Director Placement Options

The following terms and conditions apply to the Director Placement Options:

(a) Entitlement

Each Option entitles the holder to subscribe for one (1) Share upon exercise of the Option.

(b) Exercise Price

Subject to paragraph (i), the amount payable upon exercise of each Option is \$0.048 (**Exercise Price**).

(c) Expiry Date

Each Option will expire at 5:00pm (AWST) on 30 November 2030 (**Expiry Date**). An Option not exercised before the Expiry Date will automatically lapse on the Expiry Date.

(d) Exercise Period

The Options are exercisable at any time on or prior to the Expiry Date (**Exercise Period**).

(e) Notice of Exercise

The Options may be exercised during the Exercise Period by notice in writing to the Company in the manner specified on the Option certificate (**Notice of Exercise**) and payment of the Exercise Price for each Option being exercised in Australian currency by electronic funds transfer or other means of payment acceptable to the Company.

(f) Exercise Date

A Notice of Exercise is only effective on and from the later of the date of receipt of the Notice of Exercise and the date of receipt of the payment of the Exercise Price for each Option being exercised in cleared funds (**Exercise Date**).

(g) Timing of issue of Shares on exercise

Following the Exercise Date and within the time period specified by the ASX Listing Rules, the Company will:

- (i) issue the number of Shares required under these terms and conditions in respect of the number of Options specified in the Notice of Exercise and for which cleared funds have been received by the Company;
- (ii) if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and
- (iii) if admitted to the official list of ASX at the time, apply for official quotation on ASX of Shares issued pursuant to the exercise of the Options.

If a notice delivered under (g)(ii) for any reason is not effective to ensure that an offer for sale of the Shares does not require disclosure to investors, the Company must, no later than 20 Business Days after becoming aware of such notice being ineffective, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things

necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors.

(h) Shares issued on exercise

Shares issued on exercise of the Options rank equally with the then issued shares of the Company.

(i) Reconstruction of capital

If at any time the issued capital of the Company is reconstructed, all rights of a holder are to be changed in a manner consistent with the Corporations Act and the ASX Listing Rules at the time of the reconstruction.

(j) Participation in new issues

There are no participation rights or entitlements inherent in the Options and holders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Options without exercising the Options.

(k) Transferability

Subject to the Board's discretion, the Options are transferable subject to any restriction or escrow arrangements imposed by ASX or under applicable Australian securities laws.

(l) Quotation

Subject to the Board's discretion, the Company may seek quotation of the Options in accordance with the ASX Listing Rules and Corporations Act, subject to satisfaction of the minimum quotation requirements of the ASX Listing Rules. In the event that the Board elects not to obtain quotation, or quotation of the Options cannot be obtained, the Options will remain unquoted.

SCHEDULE 4 – Nomination of Auditor

20 October 2026

The Directors
Patrys Limited
Ground Floor, 168 Stirling Highway
Nedlands, Western Australia 6009


Dear Directors,

NOMINATION OF AUDITOR

For the purpose of section 328B(1) of the *Corporations Act 2001* (Cth), and being a member of Patrys Limited (ACN 123 055 363) (**Company**), I, Peter Christie as a director of Eantage Pty Ltd, being a Shareholder of the Company, hereby nominate RSM Australia Partners for appointment as auditor of the Company at the Company's 2026 annual general meeting.

Please distribute copies of this notice of nomination as required by section 328B(3) of the *Corporations Act 2001* (Cth).

Signed and dated 20 October 2026:



Peter Christie
Director
Eantage Pty Ltd

Your proxy voting instruction must be received by **1:00pm (AWST) on Saturday, 28 November 2026**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: <https://investor.automic.com.au/#/home> Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 - APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.

Joint holding: Where the holding is in more than one name, all Shareholders should sign.

Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Email Address: Please provide your email address in the space provided.

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at <https://automicgroup.com.au>.

Lodging your Proxy Voting Form:

Online

Use your computer or smartphone to appoint a proxy at <https://portal.automic.com.au/investor/home> or scan the QR code below using your smartphone

Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.



BY MAIL:

Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:

meetings@automicgroup.com.au

BY FACSIMILE:

+61 2 8583 3040

All enquiries to Automic:

WEBSITE:

<https://automicgroup.com.au>

PHONE:

1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

